Orexo’s annual report for 2013 released
Orexo’s annual report for the 2013 fiscal year has been published and can be downloaded from the investor section of the company’s homepage www.orexo.com/ar/2013/en/.
For further information, please contact:
Beata Augenblick, Investor Relations
Tel: +46-18 780 88 50, E-mail: firstname.lastname@example.org
Orexo is a specialty pharmaceutical company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. The company is commercializing its proprietary product, ZUBSOLV® (buprenorphine and naloxone), in the United States for maintenance treatment of opioid dependence. ZUBSOLV is a novel sublingual formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the EU, US and Japan. Orexo’s development expertise is within the area of reformulation technologies, and especially sublingual formulations. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.
For information about Orexo, please visit www.orexo.com
Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Markets Act. The information was submitted for publication at 1:15 pm CET on March 25, 2014.